Early research (Phase 1)Study completedNCT02587455What this trial is testingPembrolizumab and Palliative Radiotherapy in LungWho this might be right forThoracic Tumours Royal Marsden NHS Foundation Trust 24
Not applicableNot Yet RecruitingNCT06766591What this trial is testingIvonescimab Combined With Chemotherapy for the Treatment of Leptomeningeal Metastases Failed to EGFR-TKIsWho this might be right forNSCLCChemotherapyLeptomeningeal Metastases+2 more Jiangsu Province Nanjing Brain Hospital 36
Early research (Phase 1)Study completedNCT04501276What this trial is testingA Phase 1b/2 Study of ADG116, ADG116 Combined With Anti-PD-1 Antibody or Anti-CD137 Antibody in Solid Tumors PatientsWho this might be right forAdvanced/Metastatic Solid Tumors Adagene Inc 72
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07576725What this trial is testingLow Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO TrialWho this might be right forClinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8+40 more Fred Hutchinson Cancer Center 50
Testing effectiveness (Phase 2)Looking for participantsNCT07447570What this trial is testingIparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCCWho this might be right forHead and Neck CancerRadiotherapyAnti-PD-1/CTLA-4 Antibody Second Affiliated Hospital, Zhejiang University, School of Medicine 27
Testing effectiveness (Phase 2)Study completedNCT03155425What this trial is testingPD-1 Antibody SHR-1210 in Patients With Relapsed or Refractory Classic Hodgkin's LymphomaWho this might be right forHodgkin Lymphoma, Adult Jiangsu HengRui Medicine Co., Ltd. 75
Large-scale testing (Phase 3)Active Not RecruitingNCT05468489What this trial is testingTo Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLCWho this might be right forExtensive Stage Small Cell Lung Cancer Shanghai Henlius Biotech 200
Testing effectiveness (Phase 2)Study completedNCT03049618What this trial is testingRecombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475Who this might be right forALK Gene MutationBRAF Gene MutationEGFR Gene Mutation+9 more University of Southern California 42
Not applicableStudy completedNCT06818097What this trial is testingEfficacy of Target - Immunotherapy and XELOX Chemotherapy for Advanced HCCWho this might be right forAdvanced HCCSystemic TherapyChemotherapy+3 more Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 68
Testing effectiveness (Phase 2)UnknownNCT03363555What this trial is testingSHR-1210 in Patients With Relapsed or Refractory Extranodal NK/T Cell LymphomaWho this might be right forExtranodal NK/T-cell Lymphoma, Nasal Type Jiangsu HengRui Medicine Co., Ltd. 97
Not applicableUnknownNCT04889768What this trial is testingHIPEC Combined With Camrelizumab, Paclitaxel and S-1 for Conversion Therapy in Patients With Advanced Gastric Cancer With Peritoneal MetastasisWho this might be right forGastric Cancer, HIPEC, Anti-PD-1 Antibody Camrelizumab (SHR-1210), Chemotherapy and Surgery Zhejiang Cancer Hospital 46
Early research (Phase 1)Looking for participantsNCT07623369What this trial is testingA First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid TumorsWho this might be right forSolid TumorNon-small Cell Lung CancerHepatocellular Carcinoma+9 more Huahui Health 299
Testing effectiveness (Phase 2)UnknownNCT05115409What this trial is testingAnti-PD-1 Antibody Plus Chidamide and Rituximab Regimen in Relapsed or Refractory DLBCL (PCR)Who this might be right forRelapsed or Refractory DLBCL Sun Yat-sen University 27
Testing effectiveness (Phase 2)UnknownNCT04611711What this trial is testingPhase I/II Clinical Study of Decitabine Combined With TQB2450 Injection or Decitabine + Anlotinib Combined With TQB2450 Injection in the Treatment of PD-1 Monoclonal Antibody-resistant Digestive System TumorsWho this might be right forPatients With Digestive System Tumors Resistant to PD-1 Inhibitors Peking University 60
Post-approval studies (Phase 4)UnknownNCT05039580What this trial is testingProgrammed Cell Death Protein-1 (PD-1) Monoclonal Antibody for EBV-HLH and CAEBV as First-line TherapyWho this might be right forEBV Infection The First Affiliated Hospital of Soochow University 36
Early research (Phase 1)UnknownNCT03991559What this trial is testingA Safety Study of the Pan-immunotherapy in Patients With Unresectable/Metastatic Solid Tumors or LymphomasWho this might be right forSolid TumorLymphoma Chinese PLA General Hospital 20
Not applicableUnknownNCT03722875What this trial is testingSHR-1210 Plus Apatinib in Patients With Hepatocellular Carcinoma After SurgeryWho this might be right forHepatocellular Carcinoma Shanghai Zhongshan Hospital 45
Testing effectiveness (Phase 2)UnknownNCT04514081What this trial is testingThe Clinical Trial of Chidamide+Decitabine+Camrelizumab Versus Decitabine+Camrelizumab in Anti-PD-1 Antibody Resistant Patients With Classical Hodgkin Lymphoma.Who this might be right forHodgkin LymphomaAnti-PD-1 Antibody Resistant Chinese PLA General Hospital 200
Large-scale testing (Phase 3)UnknownNCT05049681What this trial is testingStudy of Anti-PD-1 Antibody SHR-1210 Plus Apatinib vs SHR-1210 as Second-Line Treatment of Advanced Esophageal Squamous CellWho this might be right forEsophageal Cancer Feng Wang 234
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07245901What this trial is testingSafety and Tolerability of a mRNA Vaccine Encoding Tumor-Specific Circular RNA Antigens in Combination With Anti-PD-1 Monoclonal Antibody in Patients With Advanced Solid TumorsWho this might be right forSolid Tumor Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 60